Correction to: Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
- —National Research Foundation of Korea funded by the Korean government (MIST)
- —National Cancer Center, Republic of Korea
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPancreatic and Hepatic Oncology Research · Cancer Genomics and Diagnostics · Cancer Research and Treatments
Lee MR , Woo SM , Kim MK , Han SS , Park SJ , Lee WJ , Lee DE , Choi SI , Choi W , Yoon KA , Chun JW , Kim YH , Kong SY
Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. Cancer Sci. 2024;115:1283–1295. doi: 10.1111/cas.16104 38348576 PMC11007020
In the initially published version of this article, there was a discrepancy in the representation of the last digit of the grant number. The correction has no impact on the result and conclusion of the manuscript.
Below is the corrected funding information:
This study was supported by grants from the NCC (Grant number: NCC‐1910192, NCC‐2212470 & NCC‐2310632).
We apologize for this error.